Xuantai Pharmaceutical (688247.SH) announced that recently, the company participated in the bidding for the tenth batch of national organized Pharmaceutical centralized procurement.
Zhithong Finance APP news: Xuantai Pharmaceutical (688247.SH) announced that recently, the company participated in the bidding for the tenth batch of national organized Pharmaceutical centralized procurement. According to the "Proposed Selected Results Announcement for National Pharmaceutical Centralized Procurement" issued by the National Organization for Pharmaceutical Joint Procurement Office on December 12, 2024, the company's products, carbonic acid sevira tablets and maxitentan tablets (products co-developed with Pujin Biotechnology (Taizhou) Co., Ltd.), were selected for this centralized procurement, while posaconazole enteric-coated tablets and tofacitinib citrate sustained-release tablets were not selected. The results of the centralized procurement are planned to be implemented in April 2025, with specific execution dates subject to notifications issued by various regions.
For the products not selected, on one hand, the company will work with Dealers to reorganize the existing products and channels, actively develop blank Medical Institutions by combining the current sales model, and encourage Dealers to strengthen their expansion in various terminal markets; on the other hand, the company will continue to strengthen the exploration of posaconazole enteric-coated tablets and tofacitinib citrate sustained-release tablets in the international market, expanding the products' international sales scale. The signing of procurement contracts for selected products and other subsequent matters, as well as the market sales implementation status after centralized procurement, still possess uncertainty.
